Fig. 1: Overall study design.

In the current study, we first performed a TAAD discovery GWAS in the MVP, with replication from six external datasets. Secondary analyses included a PheWAS of lead TAAD risk variants, MR analyses with known epidemiologic risk factors for disease, a series of analyses to identify causal genes, variants and cell types for TAAD leveraging colocalization techniques and scRNA-seq or snRNA-seq data, and the generation and testing of a TAAD PRS. This figure was created with the assistance of BioRender. Abbreviations: LDL-C, LDL cholesterol; HDL-C, HDL cholesterol; TG, triglycerides; SBP, systolic blood pressure; DBP, diastolic blood pressure.